Stabbing yourself with something used to carry a very specific meaning: Illness. Addiction. Emergency.

Now it’s framed as optimisation: Weight loss injections. Hormone therapy. Peptide stacks. Skin, sleep, recovery, performance. The language has softened. The intent has shifted. The behaviour has quietly normalised.

But biology hasn’t changed.

While some injectable compounds are clinically validated and tightly regulated, a growing number sit in a far less certain category - used widely, discussed openly, but supported by limited human evidence. And that creates a gap between what people are doing… and what they actually understand about what’s happening inside their body.

Definition: What are peptides?

Peptides are short chains of amino acids that function as signalling molecules in the body, regulating processes such as hormone secretion, appetite, immune response, and tissue repair (Fosgerau and Hoffmann, 2015).

Some peptides are developed into medicines, such as GLP-1 receptor agonists used in diabetes and obesity treatment. Others remain experimental, with limited clinical validation.

Why are injectable compounds becoming mainstream?

The rise in injectable use is not purely medical. It’s behavioural.

Modern drivers include:

• Increasing prevalence of obesity and metabolic disease (NHS Digital, 2023)
• Growing interest in longevity and performance optimisation
• Widespread exposure to health content via social media
• Dissatisfaction or delays within traditional healthcare systems

This has led to increased off-label and non-medical use of compounds, particularly within fitness, tech and biohacking communities.

Recent reporting highlights the rapid growth of grey-market peptide use, often sourced online and self-administered without clinical oversight.

Are peptides scientifically proven?

Some peptides are clinically proven and approved for medical use. Many peptides currently used for performance or recovery lack high-quality human evidence and regulatory approval.

1. Approved peptide therapeutics

Certain peptide-based drugs are well established, including:

• GLP-1 receptor agonists (e.g. semaglutide)
• Insulin analogues
• Certain cancer therapies

These undergo:

• Randomised controlled trials
• Regulatory approval processes
• Long-term safety monitoring

GLP-1 receptor agonists have demonstrated significant effects on weight loss and glycaemic control in large-scale clinical trials (Wilding et al., 2021).

2. Experimental and unapproved peptides

Compounds such as:

• BPC-157
• TB-500
• Melanotan II
• Growth hormone secretagogues

are widely used despite limited human data.

A review of peptide therapeutics highlights that while the field is promising, many compounds remain in early-stage research with insufficient clinical validation (Lau and Dunn, 2018).

Regulatory bodies have also raised safety concerns around unapproved peptide use, including risks of contamination, immune reactions, and unpredictable pharmacological effects (US Food and Drug Administration, 2023).

Why are people using them anyway?

Because the problem they are solving is not purely biological.

People are seeking:

• faster fat loss
• improved recovery
• control over symptoms
• improved appearance or performance

And in a world of constant optimisation, the appeal of a shortcut is powerful.

However, extrapolating the success of approved drugs to untested compounds is scientifically flawed. Without controlled trials, safety and efficacy cannot be reliably established (Colloca et al., 2020).

What are the risks of injectable peptides and steroids?

1. Unknown purity and contamination

Unregulated compounds may contain impurities, incorrect dosages, or degraded substances, increasing the risk of adverse effects (FDA, 2023).

 

2. Immune and inflammatory responses

Peptide therapeutics can trigger immunogenic reactions, particularly when purity and structure are inconsistent (Jiskoot et al., 2012).

 

3. Hormonal disruption

Exogenous hormone use, including anabolic steroids, can suppress the hypothalamic–pituitary–gonadal axis, affecting natural hormone production and fertility (Kanayama et al., 2015).

4. Cardiovascular risk

Anabolic steroid use is associated with:

• reduced HDL cholesterol
• increased LDL cholesterol
• increased cardiovascular risk

(Baggish et al., 2017)

 

5. Metabolic disruption

Some peptide compounds may influence insulin sensitivity, glucose metabolism, and appetite regulation, though effects vary and are often poorly characterised outside clinical trials (Müller et al., 2019).

 

6. Behavioural risk and escalation

Patterns of use often evolve into:

• stacking multiple compounds
• increasing doses
• self-directed experimentation

Without structured monitoring, this increases cumulative risk.

 

Where testing becomes essential

If you’re changing your biology, measuring your biology is no longer optional.

Blood testing does not eliminate risk.

But it provides:

• objective data
• early warning signs
• insight into physiological trends

Biomarkers offer a measurable way to track internal changes that are otherwise invisible.

What biomarkers should you monitor?

Key biomarkers include full blood count, lipid profile, liver function, kidney function, glucose/HbA1c, and hormone levels.

1. Full Blood Count

Used to detect elevated haematocrit, which is commonly increased with testosterone and anabolic steroid use (Bachman et al., 2010).

2. Lipid Profile

Steroid use is associated with adverse lipid changes, including reduced HDL cholesterol (Baggish et al., 2017).

3. Liver Function

Monitoring ALT and AST helps detect hepatotoxicity, particularly relevant for oral anabolic steroids (Kicman, 2008).

4. Kidney Function

Creatinine and eGFR provide insight into renal stress, especially in high-protein diets or compound use scenarios (Stevens et al., 2013).

5. Glucose and HbA1c

Monitoring glycaemic control is essential when compounds influence metabolism or appetite regulation (American Diabetes Association, 2023).

6. Hormone Panel

Includes:

• testosterone
• oestradiol
• LH and FSH

Used to assess endocrine suppression and imbalance (Kanayama et al., 2015).

7. Inflammatory markers (CRP)

Chronic inflammation is linked to long-term disease risk and may be elevated in response to physiological stress (Ridker, 2016).

Why baseline and repeat testing matters

A single test is a snapshot.

Health is dynamic.

Tracking:

• baseline
• change
• direction over time

is critical for identifying trends before clinical symptoms appear.

Longitudinal biomarker tracking is increasingly recognised as central to preventative and personalised medicine (Topol, 2019).

The bigger issue

We’ve normalised intervention faster than understanding.

The behaviour evolved. The measurement didn’t keep up. That’s where risk accumulates.

Are peptides safe to inject?

Some clinically approved peptides are safe when prescribed and monitored. Many unapproved peptides lack sufficient safety data and may carry risks.

Can blood tests detect peptide side effects?

Yes. Blood tests can identify changes in hormones, liver function, cholesterol, inflammation and metabolic health linked to peptide or steroid use.

Do you need to test if you’re taking peptides?

If you are using injectable compounds, testing is one of the only ways to objectively understand how your body is responding.

What is the biggest risk of unregulated peptides?

Unknown purity, lack of clinical evidence, and unpredictable biological effects.